Closing remarks - Milan 2023 - ERS Respiratory Channel

ALERT 1: pharmacological treatments

Chair(s): Katerina Antoniou, Michael Kreuter, Marlies S. Wijsenbeek, Dave Singh

Session type: Clinical trials session

Closing remarks

EVENTS HOME

Replay

Previous presentation

Next presentation

Session content

RCT Abstract - Acetazolamide to prevent impending altitude-related adverse health effects in COPD patients. RCT

Michael Furian

Replay

Abstract

Slides

RCT Abstract - High-dose (40 mg) versus low-dose (20 mg) prednisolone for treating sarcoidosis: a randomised trial (SARCORT trial)

Sahajal Dhooria

Replay

Abstract

Slides

Late Breaking Abstract - SHAMAL: reduction of maintenance inhaled corticosteroids in patients with severe eosinophilic asthma treated with benralizumab: a randomised phase 4 study

David J Jackson

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Dave Singh

Replay

Slides

RCT Abstract - BMS-986278 for progressive pulmonary fibrosis (PPF): results from a phase 2 randomized controlled trial

Tamera Corte

Replay

Abstract

Slides

RCT Abstract - Safety and efficacy of idrevloride in people with primary ciliary dyskinesia: a double-blind, randomized, placebo-controlled crossover trial (CLEAN-PCD)

Thomas Ferkol

Replay

Abstract

Slides

RCT Abstract - ScanCLAD: a Scandinavian multicenter randomized study evaluating if once-daily tacrolimus versus twice-daily cyclosporine reduces the 3-year incidence of chronic lung allograft dysfunction after lung transplantation

Goran Dellgren

Replay

Abstract

Slides

Wrap-up by discussant and discussion

Katerina Antoniou

Replay

Slides

Closing remarks

Replay

Session aims

The ALERT sessions (Abstracts Leading to Evolution in Respiratory Medicine Trials) showcase important and very late-breaking clinical trial data from all respiratory disease areas. Presenters, discussants, session chairs and the audience will actively discuss the showcased trials.

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}